Jan
20
Texas Risperdal Trial Ends When Janssen Settles For $ 158M, Company Says
January 20, 2012 | Leave a Comment
AUSTIN, Texas – Johnson & Johnson subsidiary Janssen LLP said Jan. 19 that it has agreed to pay $ 158 million to settle claims by Texas that it defrauded the Medicaid program through its off-label promotion of the atypical antipsychotic drug Risperdal (State of Texas, ex rel. Allen Jones v. Janssen LP, No. D-1GV-04-001288, Texas Dist., Travis Co.).
LexisNexis® Mealey’s™ Daily Legal News